Drug Assistance Programs Show Tightening Government Safeguards
This article was originally published in The Pink Sheet Daily
HHS Office of Inspector General releases flurry of advisories on patient assistance programs for outpatient drugs.
You may also be interested in...
US OIG's first-ever rescission means the advisory is revoked retroactively to its date of issue, which could lead to anti-kickback enforcement actions against behavior by the charity and manufacturer donors since then.
An HHS Office of Inspector General "1special advisory bulletin" on manufacturer-sponsored patient assistance programs for Medicare Part D beneficiaries will force companies to restructure these programs
Packaging for such products reflects ‘unique circumstances’ that should exempt them from the rebates on discarded drugs otherwise required by the policy, stakeholders tell CMS at a ‘town hall’ forum.